[go: up one dir, main page]

PE20090729A1 - Moduladores de gamma-secretasa - Google Patents

Moduladores de gamma-secretasa

Info

Publication number
PE20090729A1
PE20090729A1 PE2008000792A PE2008000792A PE20090729A1 PE 20090729 A1 PE20090729 A1 PE 20090729A1 PE 2008000792 A PE2008000792 A PE 2008000792A PE 2008000792 A PE2008000792 A PE 2008000792A PE 20090729 A1 PE20090729 A1 PE 20090729A1
Authority
PE
Peru
Prior art keywords
alkyl
imidazol
aryl
phenyl
methyl
Prior art date
Application number
PE2008000792A
Other languages
English (en)
Inventor
Zhaoing Zhu
William J Greenlee
Zhong-Yue Sun
Gioconda Gallo
Theodros Asberom
Xianhai Huang
Xiaohong Zhu
Mark D Mcbriar
Dmitri A Pissarnitski
Zhiqiang Zhao
Ruo Xu
Hongmei Li
Anandan Palani
Johannes H Voigt
Robert D Mazzola
John Clader
Hubert B Josien
Jun Qin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39591885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090729(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090729A1 publication Critical patent/PE20090729A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE U ES -CR5 O N; G ES O O S; V ES UN ENLACE, O, -C(O)- O N(R14); R14 ES H, ALQUILO, CICLOALQUILO, ARILALQUILO, ENTRE OTROS; R1 ES H, HALO, ALQUILO, ALQUENILO, ARILO, ENTRE OTROS; R2 ES H, ARILO, CICLOALQUILO, ALQUILARILO, ENTRE OTROS; R5, R6 Y R7 SON H, -C(O)R15, -C(O)OR15, ENTRE OTROS; R15 ES H, ALQUILO, HETEROCICLILO, HETEROARILO, ENTRE OTROS; R8 ES H, HALO, -CN, -OR15, -SR15, ENTRE OTROS; R10 ES UN ENLACE, ALQUILO, ARILO, HETEROCICLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (8Z)-3(R)-(4-FLUOROFENIL)-5,6-DIHIDRO-8-[[3-METOXI-4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL]METILEN]-3,6(S)-DIMETIL-3H,8H-[1,2,4]OXADIAZOLO[3,4-c][1,4]OXAZINA, (8E)-3-(3,5-DIFLUOROFENIL)-5,6,7,8-TETRAHIDRO-8-[[3-METOXI-4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL]METILEN]-3H-[1,2,4]OXADIAZOLO[4,3-a]PIRIDIN-3-METANOL, (+)-(8'E)-5-FLUORO-2,3,5',6',7',8'-HEXAHIDRO-8'-[[3-METOXI-4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL]METILEN]ESPIRO[1H-INDEN-1,3'-[3H][1,2,4]OXADIAZOLO[4,3-a]PIRIDINA], ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA GAMMA-SECRETASA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES QUE INCLUYEN TRANSTORNOS DEL SISTEMA NERVIOSO CENTRAL TALES COMO LA ENFERMEDAD DE ALZHEIMER Y OTRAS ENFERMEDADES RELACIONADAS CON LOS DEPOSITOS AMIELOIDES
PE2008000792A 2007-05-07 2008-05-06 Moduladores de gamma-secretasa PE20090729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91645807P 2007-05-07 2007-05-07

Publications (1)

Publication Number Publication Date
PE20090729A1 true PE20090729A1 (es) 2009-06-24

Family

ID=39591885

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000792A PE20090729A1 (es) 2007-05-07 2008-05-06 Moduladores de gamma-secretasa

Country Status (17)

Country Link
US (1) US8357682B2 (es)
EP (1) EP2155737A1 (es)
JP (1) JP5209043B2 (es)
KR (1) KR20100017573A (es)
CN (1) CN101809019A (es)
AR (1) AR066459A1 (es)
AU (1) AU2008248129B8 (es)
CA (1) CA2686589A1 (es)
CL (1) CL2008001303A1 (es)
CO (1) CO6241124A2 (es)
EC (1) ECSP099720A (es)
IL (1) IL201960A0 (es)
MX (1) MX2009012177A (es)
PE (1) PE20090729A1 (es)
RU (1) RU2009144998A (es)
TW (1) TW200909429A (es)
WO (1) WO2008137139A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
EP1953154A4 (en) 2005-11-24 2013-11-20 Eisai R&D Man Co Ltd CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
AU2008248129B8 (en) 2007-05-07 2013-05-30 Merck Sharp & Dohme Corp. Gamma secretase modulators
RU2009148866A (ru) 2007-06-01 2011-07-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
WO2009028588A1 (ja) 2007-08-31 2009-03-05 Eisai R & D Management Co., Ltd. 多環式化合物
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
WO2010054067A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
JP2012508180A (ja) * 2008-11-06 2012-04-05 シェーリング コーポレイション γ−セクレターゼ調節剤
RU2011123862A (ru) 2008-11-13 2012-12-20 Шеринг Корпорейшн Модуляторы гамма-секретазы
PA8854101A1 (es) * 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
ES2481715T3 (es) 2009-02-06 2014-07-31 Janssen Pharmaceuticals, Inc. Compuestos heterocíclicos bicíclicos sustituidos novedosos como moduladores de gamma-secretasa
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
AU2010262036B2 (en) 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
CA2784765A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
CN103502225B (zh) 2011-03-24 2015-11-25 杨森制药公司 作为γ分泌酶调节剂的经取代的三唑基哌嗪以及三唑基哌啶衍生物
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
AU2012285931B2 (en) 2011-07-15 2017-01-12 Cellzome Limited Novel substituted indole derivatives as gamma secretase modulators
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
JP6134654B2 (ja) * 2012-02-08 2017-05-24 武田薬品工業株式会社 複素環化合物およびその用途
KR102096625B1 (ko) 2012-05-16 2020-04-03 얀센 파마슈티칼즈, 인코포레이티드 (무엇보다도) 알츠하이머병의 치료에 유용한 치환 3,4-디하이드로-2h-피리도[1,2-a]피라진-1,6-디온 유도체
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
KR102209418B1 (ko) 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
CA2891755C (en) 2013-01-17 2021-10-26 Janssen Pharmaceutica Nv Substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
WO2018071535A1 (en) * 2016-10-14 2018-04-19 Merial, Inc. Pesticidal and parasiticidal vinyl isoxazoline compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1228142A (es) * 1967-03-31 1971-04-15
US4014377A (en) * 1976-08-09 1977-03-29 United States Gypsum Company Structure for slidable doors having snap-mounted glide retainer
US7065253B2 (en) 1999-09-03 2006-06-20 Intel Corporation Wavelet zerotree coding of ordered bits
KR100394083B1 (ko) * 2000-12-04 2003-08-06 학교법인 성신학원 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US20070293538A1 (en) 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
JP2007538024A (ja) 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
AU2008248129B8 (en) 2007-05-07 2013-05-30 Merck Sharp & Dohme Corp. Gamma secretase modulators

Also Published As

Publication number Publication date
JP5209043B2 (ja) 2013-06-12
AU2008248129A8 (en) 2013-05-30
US20100247514A1 (en) 2010-09-30
EP2155737A1 (en) 2010-02-24
AR066459A1 (es) 2009-08-19
CA2686589A1 (en) 2008-11-13
ECSP099720A (es) 2009-12-28
KR20100017573A (ko) 2010-02-16
AU2008248129B8 (en) 2013-05-30
WO2008137139A1 (en) 2008-11-13
AU2008248129A1 (en) 2008-11-13
IL201960A0 (en) 2010-06-16
AU2008248129B2 (en) 2013-05-23
RU2009144998A (ru) 2011-06-20
CO6241124A2 (es) 2011-01-20
JP2010526808A (ja) 2010-08-05
TW200909429A (en) 2009-03-01
CL2008001303A1 (es) 2008-11-14
CN101809019A (zh) 2010-08-18
MX2009012177A (es) 2009-11-23
US8357682B2 (en) 2013-01-22

Similar Documents

Publication Publication Date Title
PE20090729A1 (es) Moduladores de gamma-secretasa
PE20091095A1 (es) Moduladores de gamma secretasa
PE20230106A1 (es) Compuestos de pirimidina fusionados como moduladores de kcc2
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20091977A1 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa-7
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
PE20180500A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
MA31373B1 (fr) Composes amino-heterocycliques
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20041059A1 (es) Quinazolinas como moduladores de canales ionicos
PE20171342A1 (es) Compuestos y su uso como inhibidores de bace
PE20050265A1 (es) Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1)
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
PE20081559A1 (es) DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
UY24016A1 (es) Derivados triciclicos del pirazol
PE20090957A1 (es) Moduladores de gamma secretasa
PE20091194A1 (es) Derivados de heterociclicos como moduladores del receptor m1
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
CO6382118A2 (es) Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio
PE20081462A1 (es) Bifenilsulfonilos y fenil heteroaril sufonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal

Legal Events

Date Code Title Description
FC Refusal